Publications by authors named "Amanda Ceas"
Background: Allogeneic bone marrow transplant (alloBMT) is curative for hematologic malignancies through the graft-versus-tumor (GVT) effect but has been ineffective for solid tumors like osteosarcoma (OS). OS expresses CD155 which interacts strongly with inhibitory receptors TIGIT and CD96 but also binds to activating receptor DNAM-1 on natural killer (NK) cells. CD155 has never been targeted after alloBMT.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers discovered a new type II JAK2 inhibitor that blocks the enzyme in its inactive form, showing better performance in mouse models of polycythemia vera.
- * They identified a specific mutation (JAK2 G993A) that makes some type II inhibitors ineffective, but not their new compounds, which could lead to better treatments that resist such mutations.